Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Exagen Inc. reported revenue of $18.4 million for Q3 2026, a 6.8% increase year-over-year, while narrowing its net loss to $6.3 million compared to $7.1 million in Q3 2025. The company strengthened its capital position through $6.4 million in net proceeds from an at-the-market (ATM) equity offering during the quarter.
Allison Transmission is hosting an 'Off-Highway Analyst Teach-In Day' to present its strategic growth priorities and expanded propulsion solutions portfolio. The presentation highlights the company's positioning in high-growth end markets including infrastructure, data centers, and defense. Management is using the event to showcase a transformed business model focused on integrated mobility solutions across conventional, hybrid, and electric technologies.
Safe Pro Group Inc. was awarded a $2.5 million U.S. Government Prime Contract to provide its Super Intelligence (SI) threat detection and mapping software for the U.S. Army's Abrams Tanks. The company will team with Anduril Industries to integrate its software onto the Ghost-X drone platform to enable real-time identification and geolocation of over 150 types of explosive threats.
Nika Pharmaceuticals, Inc. reported a net loss of $46,077 for the nine months ended September 30, 2026, compared to a loss of $39,309 in the prior year period. The company remains in a pre-revenue stage with a total stockholders' deficit of $343,705 and is primarily funded through loans from related parties.
Stabilis Solutions Wins Contract from commercial aerospace customer
Stabilis Solutions entered into a three-year take-or-pay LNG supply agreement with an existing commercial aerospace customer to support operations at the John C. Stennis Space Center. The contract, running from January 2027 through December 2029, requires a minimum purchase of 230,000 gallons of LNG per month, primarily supplied from the company's Port Allen facility.
Veradermics reported Q3 2026 financial results and highlighted clinical progress for its lead candidate VDPHL01, which recently achieved positive Phase 3 and Phase 2/3 results in male pattern hair loss. The company ended the quarter with $798.4 million in cash, which is expected to fund operations into 2030 through potential commercial launch.
“This has been a defining year for Veradermics as we advanced the development of VDPHL01 as a potential treatment for pattern hair loss in both men and women. In men, we reported topline results from two positive registration-directed trials, Studies ‘302’ and ‘304’, which collectively enrolled more than 1,000 male participants and demonstrated early, consistent, and robust hair growth.”
Reid Waldman, M.D., Chief Executive Officer of Veradermics
“These accomplishments bring us closer to addressing a significant unmet need in pattern hair loss for both men and women. We remain well capitalized to continue the development of VDPHL01 and advance preparations for a potential commercial launch, with the goal of establishing VDPHL01, if approved, as a foundational treatment for pattern hair loss.”
Reid Waldman, M.D., Chief Executive Officer of Veradermics
ACCESS Newswire reported Q3 2026 financial results with revenue of $5.5 million and a gross margin expansion to 75%. The company achieved an Adjusted EBITDA margin of 15% and positive cash flow from operations of $469,000 despite a slight year-over-year revenue decrease due to lower press release volumes.
Term
Q3 2026
“Our third quarter demonstrated the resilience of our business model in a rapidly evolving news distribution market. We increased the number of active customers by 14% year-over-year, expanded gross margin to 75%, grew average revenue per release, and built continued momentum and revenue contribution from our Insight & Analytics, social monitoring and PRO offerings.”
Brian R. Balbirnie, ACCESS Newswire’s Founder and Chief Executive Officer
“In October we streamlined our organization across sales, development, editorial and operations, which we expect to generate annualized savings over $1.5 million, with a partial benefit in the fourth quarter and the full benefit beginning in the first quarter of 2027 and beyond.”
Brian R. Balbirnie, ACCESS Newswire’s Founder and Chief Executive Officer
Csquare, Inc. reported a net loss of $88.1 million for the third quarter of 2026, compared to a $29.8 million loss in the prior year, despite a 25.6% increase in revenues to $302.3 million. The company completed its initial public offering during the quarter, raising approximately $1.14 billion and converting its member's interest into common stock.
Cosmos Health Inc. has filed a Certificate of Amendment to its Articles of Incorporation to effect a 1-for-20 reverse stock split of its outstanding common stock. The split is scheduled to become effective on November 12, 2026, while the company's authorized share count will remain unchanged at 1.5 billion shares.
Virginia National Bankshares Corporation declared an 8% stock dividend and an increased quarterly cash dividend of $0.38 per share. The stock dividend will be paid on November 30, 2026, followed by the cash dividend on December 15, 2026, which represents a $0.02 per share increase over the previous quarter.
Terrestrial Energy reported its Q3 2026 financial results, highlighting its selection as the advanced nuclear technology supplier for Ameresco's project at the U.S. Army’s Aberdeen Proving Ground. The company ended the quarter with $276.3 million in cash and no debt while completing its 2026 guidance for NRC topical report submissions.
Term
Q3 2026
“Our selection for Ameresco’s project with the U.S. Army extends our commercial pipeline into the federal government and defense, and with our Thermal and Electric Facility Topical Report, we delivered on our guidance of at least three submissions to the NRC this year.”
Simon Irish, Chief Executive Officer of Terrestrial Energy
“We are focused on the race to fleet deployment, and on delivering nuclear power at fleet scale. The world needs innovative nuclear plants for new sources of clean, firm, affordable energy, and those fundamentals continue to strengthen supporting our business plan.”
Simon Irish, Chief Executive Officer of Terrestrial Energy
Vtex Chief Strategy Officer Andre Spolidoro Ferreira Gomes Sells $81.8K of Stock
Andre Spolidoro Ferreira Gomes, Chief Strategy Officer, sold 20,804 shares of Vtex at $3.93 a share, worth $81.8K in total on Nov 9, 2026. Shares held after the trade: 282,027 (-6.9%).
Azitra announced positive ex vivo human skin model data for its ATR-COSF program, showing a 56% reduction in wrinkles and improved skin elasticity. The company plans to initiate a first-in-human study for the filaggrin-based topical cosmetic with initial results expected by year-end 2026. Additionally, the company provided updates on its ATR-04 Phase 1/2 trial, which has been expanded to include patients with rashes from KRAS and MEK inhibitors.
EquipmentShare.com Inc filed its Q3 2026 10-Q reporting a significant increase in accounts receivable from $748 million at year-end 2025 to $1.154 billion as of September 30, 2026. The company continues to focus on its 'OWN Program' capital-light fleet growth model and its T3 cloud-based platform while maintaining a cash balance of $359 million.
Rackspace Technology raised approximately $66 million through private placements of its common stock. The company issued 18,181,816 shares to Voss Capital for $50 million and an additional 5,818,181 shares to other purchasers for $16 million to fund general corporate purposes and GPU-related growth initiatives.
Intelligent Bio Solutions Inc. reported a net loss of $2.67 million for the quarter ended September 30, 2026, an improvement from the $2.99 million loss in the prior year. Revenue grew 25% to $1.39 million, while the company strengthened its liquidity position with cash and cash equivalents increasing to $5.93 million, primarily through financing activities.
Flex Ltd. is hosting an Innovation Day at its Austin headquarters to present strategic information regarding the company and Axiom Solutions International, Inc. Axiom is the planned independent, publicly-traded company that will comprise Flex's Cloud and Power Infrastructure segment following a proposed tax-free spin-off.
Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.
PowerCompute reported its Bitcoin mining and operating results for October 2026, mining 9.0 Bitcoin, a 20% increase year-over-year. The company increased its active hashrate to 800 PH/s by installing 900 more efficient miners on its existing 26 megawatts of power infrastructure.
Maxcyte Signs $125M M&A Deal with Akron BioProducts LLC
MaxCyte has entered into a definitive agreement to acquire Akron BioProducts LLC for $105 million in cash, $20 million in deferred cash payments, and approximately 20.6 million shares of common stock. The acquisition of the GMP-grade reagent supplier is expected to nearly double MaxCyte's revenue and expand its cell therapy manufacturing offerings. The deal is expected to close before the end of 2026, subject to regulatory approvals.
Value
$125M
Counterparty
Akron BioProducts LLC
“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”
Dominari Holdings reported Q3 2026 revenue of $16.4 million, a 69% decrease year-over-year primarily due to lower underwriting and commission revenue. Despite the revenue decline, the company narrowed its sequential net loss to $1.9 million through a 65% reduction in operating expenses and highlighted a 341% increase in annual recurring revenue (ARR) to $3.6 million.
Worthington Enterprises, Inc. is hosting an Investor and Analyst Day on November 10, 2026, to discuss the company's strategic outlook and business plans. The company filed a formal investor presentation deck and a related news release as exhibits to the 8-K. The presentation covers expectations for future growth, performance, and shareholder value following its transformation efforts.
KULR Technology Group reported Q3 2026 revenue of $7.4 million, a 197% year-over-year increase driven by a nearly fourfold jump in product sales. The company completed its exit from Bitcoin mining, resulting in a $15.8 million non-recurring gain and a cash balance of $54.5 million with zero debt. Management also implemented a reduction in force expected to save $4 million annually as it shifts focus toward its KULR ONE battery platform.
Term
Q3 2026
“In the third quarter, we delivered on the three measures that matter for 2026: product revenue growth, gross margin improvement and cost discipline. Product sales nearly quadrupled year-over-year, and the growth came from our KULR ONE platform. Gross margin returned to positive territory, though it is not yet where this business can run. We completed our exit from Bitcoin, repaid our only debt and ended the quarter with $54.5 million in cash.”
Michael Mo, Founder and CEO of KULR Technology Group
Atossa Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its (Z)-endoxifen clinical programs. The company highlighted a new contingent value rights (CVR) agreement that entitles shareholders to 25% of net proceeds (up to $50 million) from the potential future sale of its first FDA priority review voucher.
Term
Q3 2026
“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs. Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs. At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027.”
Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer
KULR Technology Group reported a significant revenue increase to $7.4 million for the third quarter of 2026, up from $2.5 million in the prior year period. Despite this growth, the company realized a net loss of $46.5 million for the first nine months of 2026, largely driven by a $15.6 million decrease in the fair value of digital assets and increased research and development expenses.
Artificial Intelligence Technology Solutions Business Update
Artificial Intelligence Technology Solutions (AITX) provided a progress update on its 15-initiative product roadmap, reporting that four initiatives have been released and two are in partial release. The company is concentrating its engineering resources on its RAIA, ROAMEO, and SARA platforms to support its goal of reaching monthly operating cash breakeven by January 2027.
Tyra Biosciences reported a net loss of $51.1 million for the third quarter of 2026, driven by increased research and development expenses. The company significantly strengthened its balance sheet during the first nine months of 2026, raising over $524 million through an at-the-market offering and a separate issuance of common stock and pre-funded warrants.
Cingulate Inc. provided a regulatory update on its lead ADHD asset, CTx-1301, following a previously received FDA Complete Response Letter (CRL). The company has substantially completed the required manufacturing work to address the FDA's requests and expects to resubmit its New Drug Application (NDA) between December 2026 and January 2027.
Coya Therapeutics reported a net loss of $24.5 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company expressed substantial doubt about its ability to continue as a going concern, noting that its $35.8 million in cash and cash equivalents is insufficient to fund operations for more than one year.
TriSalus Life Sciences reported a net loss of $16.5 million for the nine months ended September 30, 2026, an improvement from a $29.5 million loss in the prior year period. Revenue grew to $33.2 million, while the company strengthened its balance sheet with cash and cash equivalents increasing to $41.1 million.